Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.97 USD
+0.05 (0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $11.96 -0.01 (-0.08%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Roivant Sciences Ltd falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6,536 | 1,677 | 2,064 | 2,133 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 196 | 122 | 82 | 54 | NA |
Total Current Assets | 6,732 | 1,799 | 2,147 | 2,187 | NA |
Net Property & Equipment | 19 | 39 | 26 | 15 | NA |
Investments & Advances | 248 | 304 | 326 | 290 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 138 | 145 | 0 | 0 | NA |
Deposits & Other Assets | 39 | 49 | 26 | 36 | NA |
Total Assets | 7,222 | 2,390 | 2,585 | 2,590 | NA |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 53 | 38 | 35 | 21 | NA |
Current Portion Long-Term Debt | 12 | 41 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 176 | 167 | 128 | 77 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 16 | 15 | 11 | 109 | NA |
Total Current Liabilities | 267 | 272 | 184 | 219 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 14 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 431 | 376 | 210 | 170 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 29 | 81 | 53 | 76 | NA |
Minority Interest (Liabilities) | 0 | 0 | 22 | 22 | NA |
Total Liabilities | 774 | 782 | 546 | 550 | NA |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 5,396 | 4,933 | 4,422 | 3,815 | NA |
Retained Earnings | 576 | -3,773 | -2,764 | -1,918 | NA |
Other Equity | 476 | 447 | 381 | 143 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 6,449 | 1,608 | 2,039 | 2,040 | NA |
Total Liabilities & Shareholder's Equity | 7,222 | 2,390 | 2,585 | 2,590 | NA |
Total Common Equity | 6,449 | 1,608 | 2,039 | 2,040 | 0 |
Shares Outstanding | 806.60 | 760.10 | 694.90 | 15.00 | NA |
Book Value Per Share | 7.99 | 2.11 | 2.93 | 135.97 | 0.00 |
Fiscal Year End for Roivant Sciences Ltd falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5,679 | 6,536 | 6,671 | 1,408 | 1,434 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 323 | 196 | 136 | 143 | 127 |
Total Current Assets | 6,002 | 6,732 | 6,807 | 1,552 | 1,561 |
Net Property & Equipment | 18 | 19 | 22 | 24 | 36 |
Investments & Advances | 263 | 248 | 240 | 250 | 296 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 136 | 138 | 150 | 141 | 145 |
Deposits & Other Assets | 33 | 39 | 47 | 50 | 46 |
Total Assets | 6,496 | 7,222 | 7,313 | 2,066 | 2,137 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 28 | 53 | 35 | 44 | 50 |
Current Portion Long-Term Debt | 12 | 12 | 46 | 49 | 44 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 138 | 176 | 122 | 153 | 119 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 28 | 16 | 31 | 9 | 20 |
Total Current Liabilities | 215 | 267 | 245 | 266 | 245 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 312 | 431 | 403 | 389 | 385 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29 | 33 | 36 | 121 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 601 | 774 | 728 | 740 | 803 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 4,782 | 5,396 | 5,390 | 5,321 | 4,982 |
Retained Earnings | 671 | 576 | 727 | -4,369 | -4,065 |
Other Equity | 442 | 476 | 467 | 374 | 417 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5,895 | 6,449 | 6,585 | 1,326 | 1,334 |
Total Liabilities & Shareholder's Equity | 6,496 | 7,222 | 7,313 | 2,066 | 2,137 |
Total Common Equity | 5,895 | 6,449 | 6,585 | 1,326 | 1,334 |
Shares Outstanding | 739.00 | 806.60 | 804.80 | 800.70 | 767.10 |
Book Value Per Share | 7.98 | 7.99 | 8.18 | 1.66 | 1.74 |